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Summary
Background Primary spontaneous pneumothorax occurs in otherwise healthy young patients. Optimal management is 
not defined and often results in prolonged hospitalisation. Data on efficacy of ambulatory options are poor. We aimed 
to describe the duration of hospitalisation and safety of ambulatory management compared with standard care.
Methods In this open-label, randomised controlled trial, adults (aged 16–55 years) with symptomatic primary 
spontaneous pneumothorax were recruited from 24 UK hospitals during a period of 3 years. Patients were randomly 
assigned (1:1) to treatment with either an ambulatory device or standard guideline-based management (aspiration, 
standard chest tube insertion, or both). The primary outcome was total length of hospital stay including re-admission 
up to 30 days after randomisation. Patients with available data were included in the primary analysis and all assigned 
patients were included in the safety analysis. The trial was prospectively registered with the International Standard 
Randomised Clinical Trials Number, ISRCTN79151659.
Findings Of 776 patients screened between July, 2015, and March, 2019, 236 (30%) were randomly assigned to 
ambulatory care (n=117) and standard care (n=119). At day 30, the median hospitalisation was significantly shorter in 
the 114 patients with available data who received ambulatory treatment (0 days [IQR 0–3]) than in the 113 with available 
data who received standard care (4 days [IQR 0–8]; p<0·0001; median difference 2 days [95% CI 1–3]). 110 (47%) of 
236 patients had adverse events, including 64 (55%) of 117 patients in the ambulatory care arm and 46 (39%) of 119 in 
the standard care arm. All 14 serious adverse events occurred in patients who received ambulatory care, eight (57%) of 
which were related to the intervention, including an enlarging pneumothorax, asymptomatic pulmonary oedema, and 
the device malfunctioning, leaking, or dislodging.
Interpretation Ambulatory management of primary spontaneous pneumothorax significantly reduced the duration of 
hospitalisation including re-admissions in the first 30 days, but at the expense of increased adverse events. This data 
suggests that primary spontaneous pneumothorax can be managed for outpatients, using ambulatory devices in 
those who require intervention.
Funding UK National Institute for Health Research.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license. 
Introduction
Pneumothorax is a common clinical problem. Primary 
spontaneous pneumothorax describes patients develop­
ing pneumothorax in the absence of trauma, with no 
underlying established lung pathology, and occurs in in 
approximately 3000 patients per year in the UK.1,2 Some 
patients can be managed conservatively with close obser­
vation,3,4 but many symptomatic patients require an inter­
vention to re­expand the lung. Current British Thoracic 
Society (BTS) guidelines suggest that aspiration of trapped 
air using a cannula and syringe should be considered, but 
more than 50% of patients subsequently require the inser­
tion of a chest tube, which is then attached to an underwater 
seal drainage system.4 The mean duration of hospitalisation 
of patients admitted for drainage is 6–8 days.5
Ambulatory management of patients with primary spon­
taneous pneumothorax potentially removes the need for 
long hospital admission by facilitating outpatient treatment. 
Reducing the need for chest tubes with bulky underwater 
systems might allow patients to remain mobile and 
facilitate early discharge with the device in situ. Ambulatory 
devices generally incorporate a Heimlich (one­way) valve, 
which replaces the traditional underwater seal, either by in­
line attachment to a standard chest tube or as part of an 
integrated device. However, the efficacy and safety of this 
approach has yet to be rigorously assessed. A systematic 
review6 of the literature found that 18 studies describing 
ambulatory management of both spontaneous and iat­
rogenic pneumothorax reported an overall success rate of 
86% and successful outpatient management in 78% 
of cases, with few complications. Unfortunately, the 
available evidence was described as poor quality with a high 
risk of bias, including two inadequately powered random­
ised trials and several retrospective case series.6
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The Randomised Ambulatory Management of Primary 
Pneumothorax (RAMPP) trial was done to determine 
whether ambulatory management of patients with 
primary spontaneous pneumothorax is safe and reduces 
the length of hospitalisation.
Methods
Study design
The RAMPP trial was a multicentre, open­label, random­
ised controlled trial comparing ambulatory management 
of primary spontaneous pneumothorax with standard 
care based on national guidelines.4 Participants were 
screened and recruited from 24 hospitals in the UK with 
a track record of recruiting to trials and a strong link 
between emergency and respiratory departments. Study 
oversight was provided by the trial steering committee 
and an independent data monitoring committee, and 
ethical approval was provided by the UK National 
Research Ethics Service Committee (15/SC/0240). The 
trial protocol can be found online and in the appendix 
(pp 9–47).7
Participants
Eligible patients had presented with a symptomatic 
spontaneous pneumothorax (confirmed by a chest radio­
graph or CT scan) and were aged 16–55 years (as per BTS 
definition). Once a patient was identified as having a 
primary spontaneous pneumothorax, the decision to 
intervene was made on the basis of current BTS 
guidelines: patients were enrolled if they had a large 
pneumothorax (≥2 cm interpleural distance at the level of 
the hilum) or significant symptoms, or both. Patients 
were ineligible if they had known or suspected underlying 
lung disease (including >20 pack­year tobacco smoking 
history, but excluding well controlled asthma), evidence 
of tension pneumothorax (defined as clinical or 
radiographic evidence of significantly increased intra­
pleural pressure causing haemodynamic compromise 
that requires urgent decompression), or a contraindication 
to thoracic procedure as determined by the responsible 
physician, or if they were pregnant or lactating. Patients 
requiring intervention could be enrolled and randomly 
assigned up to 24 h after presentation, provided that they 
remained hospitalised with an ongoing symptomatic 
pneumothorax despite initial intervention (eg, patients 
treated initially with aspiration and observed overnight) 
requiring chest tube insertion. Patients not requiring an 
intervention were invited to participate in an observational 
cohort up to 2 weeks after their initial presentation, the 
results of which will be published separately. All partic­
ipants in the current study provided written informed 
consent.
Randomisation and masking
Patients were randomly assigned (1:1) to either insertion 
of an ambulatory device (Rocket Pleural Vent, Rocket 
Medical, Watford, UK) or standard care (aspiration, 
standard chest tube insertion, or both) as per BTS 
guidelines.4 Randomisation was done through a cen­
tralised, web­based system using a computer­generated 
minimisation algorithm. The minimisation factors were 
the recruiting centre and size of pneumothorax at 
presentation (≥4 cm vs <4 cm at the level of the hilum on 
chest radiograph). The study was necessarily open label, 
with both patients and physicians aware of treatment 
allocation.
Procedures
Patients in the experimental arm had an ambulatory device 
inserted using sterile technique with up to 3 mg/kg lido­
caine as local anaesthetic. The device was inserted either in 
the anterior mid­clavicular line (second intercostal space) 
or mid­axillary line (fifth intercostal space) according to 
investigator preference and clinical requirement. The 
ambulatory device used was an 8F gauge catheter attached 
to a self­contained, one­way Heimlich valve and fluid 
collection chamber (appendix p 1). Researchers and local 
clinicians were trained to insert the device by the trial 
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Research in context
Evidence before this study
A search of PubMed and MEDLINE for articles on ambulatory 
management of pneumothorax published up to Dec 5, 2019, 
with the keywords “pneumothorax”, “ambulatory”, “Heimlich 
valve”, and “outpatient” showed that most studies were case 
series and included two small, inadequately powered 
randomised trials. In 2013, a systematic review of 18 studies 
found that although ambulatory options might be successful, 
the data were of poor quality with a high risk of bias. A further 
three case series were subsequently published. Given this 
uncertain evidence base, we designed the Randomised 
Ambulatory Management of Primary Pneumothorax trial as a 
controlled study to determine whether ambulatory 
management of patients with primary spontaneous 
pneumothorax reduces the length of hospitalisation and is 
safe.
Added value of this study
This study, which to our knowledge is the only large randomised 
trial of its kind, found that ambulatory management of patients 
with primary spontaneous pneumothorax significantly reduces 
the length of hospitalisation compared with standard care. 
Ambulatory patients had fewer pleural procedures, but serious 
adverse events were higher because of hospital re-admission.
Implications of all the available evidence
This trial challenges the current guidelines for management for 
patients with primary spontaneous pneumothorax, with the 
proviso that some patients will require further treatment.
See Online for appendix
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coordinator or local Principal Investigator. Following 
device insertion, patients were observed for 1–2 h to assess 
them for clinical stability, after which a chest radiograph 
was done (appendix p 44).
If the chest radiograph showed insufficient lung re­
expansion, the ambulatory device remained in situ and 
the patient was discharged, as long as the prespecified 
criteria of fitness for discharge were fulfilled. These 
criteria consisted of all of the following: the patient agreed, 
had clinically stable cardiorespiratory observations, had 
no increase in the size of pneumothorax since the last 
radiograph or review, did not require oxygen or other 
respiratory support, was mobile and able to self­care, was 
provided with written information on point of contact and 
follow­up plan, and lives with a responsible person at 
home. Any patient not meeting these criteria remained 
hospitalised and was reviewed daily. Sufficient lung re­
expansion was defined as complete or almost complete 
re­expansion (<1 cm rim of air apically on chest 
radiograph) and being unable to aspirate air through the 
device using a connector and syringe.
If discharged home with the device in situ, patients 
were reviewed as an outpatient every 1–2 days (generally 
daily, but a single review during the weekend was 
sufficient if clinically stable) until day 4, at which stage 
the patient should be considered for thoracic surgery. 
The timing of the ongoing outpatient review after day 4 
was at the discretion of the responsible clinician. After 
each review, if there was sufficient re­expansion of the 
lung and no ongoing air leak, the device was removed 
and the patient was discharged. A postremoval chest 
radiograph was done to ensure that the lung had not 
recollapsed. If the chest radiograph showed recurrence 
of pneumothorax, the patient was rehospitalised for 
observation and consideration of the placement of a 
standard chest tube connected to an underwater seal.
Patients who were in the control arm received standard 
treatment as per the 2010 BTS Pleural Guidelines.4 In 
brief, pleural aspiration (if the clinician deemed it 
appropriate) was attempted under local anaesthetic using 
a 14–16 gauge cannula and syringe, aspirating a maximum 
of 2·5 L. The patient was observed for 1–2 h to assess for 
clinical stability, and a repeat chest radiograph was done. 
If the repeat chest radiograph showed sufficient lung re­
expansion, the patient was discharged. If the lung had not 
sufficiently re­expanded, then a small­bore chest tube 
(≤14 F) was inserted and attached to an underwater seal, 
and the patient was admitted to hospital.
Although initial aspiration was recommended in the 
trial protocol, the responsible clinician was able to 
proceed directly to chest tube insertion and admission at 
their discretion, in line with BTS guidelines.4 Decisions 
regarding chest tube removal were as per standard 
practice at participating centres but included no further 
air leak (as shown by a non­bubbling chest tube) and full 
lung expansion on chest radiograph. A postremoval chest 
radiograph was done to ensure that the lung had not 
recollapsed. Fitness for discharge criteria were assessed 
daily to provide equality between treatment groups. 
Evidence for the use of suction in patients with pneu­
mothorax is poor. BTS guidelines suggest that high 
volume, low pressure suction should not be routinely 
used but could be considered if there is prolonged air 
leak.4 Use of suction was at the discretion of the local 
responsible clinician.
Patients were followed up at 1 week after the completion 
of treatment, and 30 days, 6 months, and 12 months after 
randomisation. Hospital admissions and pneumothorax 
recurrence were measured up to the day 30 follow­up 
point, and at each follow­up point, data were collected on 
further hospital admissions, pain and breathlessness 
visual analogue scale (VAS) scores, quality of life, and 
smoking status. Patients who were not able to attend 
face­to­face follow­up appointments were contacted by 
telephone to check for complications or recurrence, and 
if this was not possible, data on recurrence was collected 
through hospital or general practitioner medical records. 
Data on pneumothorax recurrence at 6 and 12 months 
will be presented separately with data from the obser­
vational cohort.
Outcomes
The primary outcome was the total length of hospital stay 
up to 30 days after randomisation, including initial 
hospital stay and re­admissions. Patients remaining in 
hospital overnight were recorded as having a 1­day stay; 
those discharged on the same day (either after successful 
needle aspiration treatment or discharge with the 
ambulatory device) were recorded as zero length of stay. 
The 30­day point was chosen on the basis of previous 
data suggesting that most conservatively treated (non­
surgical) primary spontaneous pneumothorax air leaks 
resolve within 14 days of initial treatment,8 and thus 
outcomes measured at 30 days were considered reliably 
to capture all related re­admissions. Patients with 
missing data at 1 week after treatment or 30 days after 
randomisation were assumed to have no re­admissions. 
Re­admission was defined as the need for emergency 
(non­planned) admission to hospital for any reason in 
relation to pneumothorax but was not restricted to the 
requirement for a further pleural intervention. Any re­
admission to hospital was recorded as at least a 1­day 
stay. Planned day case reviews for outpatient treated 
patients were not included.
Secondary outcomes included the need for a further 
pleural procedure, adverse events, pain and breath­
lessness VAS scores, recurrence rates, and time off work 
because of pneumothorax treatment. Further pleural 
procedures were defined as any intervention that 
punctured the pleura (eg, chest drain insertion) after 
a first treatment intervention. We obtained a daily record 
of thoracic pain and breathlessness scores using a VAS 
score up to day 4 after randomisation, which was 
measured on a scale of 0 to 100 mm. A score of 0 indicated 
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the complete absence of symptoms and 100 was the 
maximum possible level of symptoms, which is validated 
for assessment of breathlessness in patients having 
pleural procedures.9,10 VAS scores were also recorded on 
completion of treatment. Because patients could be 
discharged with a small residual pneumothorax, those 
with a persistent small pneumothorax at 1­week follow­
up were defined as having ongoing pneumotho rax rather 
than a new occurrence. The recurrence of pneumotho­
rax was defined as a new episode of symptomatic 
pneumothorax after full resolution on chest radiograph, 
or occurring after the 1­week follow­up visit. Several 
other secondary outcomes including quality of life 
questionnaires (EuroQol­5D­5L), blood parameters, and 
digital air flow analysis are planned for separate 
publications.
Concerning the failure of medical treatment, there is no 
robust evidence on the optimal timing for surgical 
intervention in primary spontaneous pneumothorax after 
initial treatment in the presence of ongoing air leak. 
Current BTS guidelines suggest that cases of persistent air 
leak or non­re­expansion should be referred for surgery 
after 3–5 days.4 To achieve objective outcomes for this 
study, the following criteria were developed to ensure 
consistent practice in both groups, and were recorded in 
all cases. Referral for thoracic surgery occurred in the 
presence of all of the following: (1) persistent air leak on 
day 4 after insertion of chest tube (as measured by bubbling 
chest tube attached to an underwater seal) or evidence of 
ongoing air leak through the ambulatory device; (2) persis­
tent pneumothorax on chest radiograph; (3) patient agreed 
to have surgery; and (4) no contraindication to thoracic 
surgery.
Safety data were collected for all patients at each trial 
visit regarding adverse events, with seriousness defined as 
per Good Clinical Practice guidelines.11 Expected adverse 
events were pain at the drainage site, minor haemorrhage 
not requiring specific intervention (eg, blood transfusion 
or surgery), subcutaneous emphysema, pleural infection, 
unintentional removal (falling out) of the Pleural Vent or 
chest tube, recurrence of pneumothorax or worsening of 
ongoing pneumothorax (if evidence of failure of full 
resolution following initial intervention), re­expansion 
pulmonary oedema, and the need for further (non­
emergency) pleural procedures. Expected serious adverse 
events included tension pneumothorax occurring during 
treatment, blockage of chest tube with clinical con­
sequences (eg, patient unwell or further procedure 
required), major intrathoracic haemorrhage requiring 
specific intervention (eg, blood transfusion), and any 
additional emergency pleural procedure as deemed 
necessary by the local investigator (eg, large bore chest 
tube insertion). Because the recurrence of pneumothorax 
is common and expected (occurring in about 33% 
of primary spontaneous pneumothorax cases within 
1 year1,12), recurrence was not reported as a serious adverse 
event. Adverse events were assessed locally, and, if they 
fulfilled the criteria for a serious adverse event,13 they were 
reported immediately (ie, within 24 h) to the Oxford 
Respiratory Trials Unit for review. All serious adverse 
events were followed until resolution.
Statistical analysis
The statistical analysis was approved by the trial stat­
isticians and steering committee before data analysis. 
The sample size for the primary outcome was determined 
to detect a difference in length of hospital stay of 2·3 days: 
from a mean of 4 days admission in patients receiving 
standard care to an expected mean of 1·7 days in patients 
receiving ambulatory care (standard deviation in both 
groups 6·0). The sample size calculation included a 
correction factor for non­normal data. These estimates 
assume that up to 50% of patients receiving standard care 
were expected to be successfully treated with aspiration 
alone (ie, zero­day admission). It was assumed, conser­
vatively, that about 20% of patients in the ambulatory care 
arm would require re­admission. Based on these param­
eters, with 80% power, a 5% two­sided significance level, 
and a 10% attrition rate, the study required 236 patients. 
Previous pleural studies have shown an attrition rate for 
the primary outcome measure of less than 5%.14–16
Figure 1: Trial profile
*Patients were classed as missed if they had already been treated for primary spontaneous pneumothorax and 
were therefore no longer eligible.
117 assigned to ambulatory care 
114 analysed for primary outcome 
102 followed up until 30 days 
3 excluded from analysis 
because data not available
12 lost to follow-up
4 before 1 week 
8 before 30 days
119 assigned to receive standard 
care (control)
113 analysed for primary outcome  
776 patients assessed for enrolment
101 followed up until 30 days 
6 excluded from analysis 
because data not available
192 allocated to observational cohort
348 excluded 
101 patient refusal 
83 no trained staff available at that time
75 presentation out of hours
60 missed*
22 living outside area
4 data missing
3 other
12 lost to follow-up
3 before 1 week 
9 before 30 days
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The Mann­Whitney U test was used for the primary 
analysis. The median hospital stay (expected to be non­
normally distributed) was calculated for each group, 
and the 95% confidence interval for median difference 
was calculated using an exact method. Pre­planned 
sensitivity analyses were done to assess the robustness 
of the primary outcome. Survival analysis techniques 
were used to compare time to discharge between the 
two groups using the Gehan­Breslow­Wilcoxon test 
(more appropriate than the log­rank test because 
of a high early event rate in primary spontaneous 
pneumothorax) and using Cox proportional hazards 
regression to calculate a hazard ratio and associated 
95% confidence interval. An analysis of hospital stay in 
hours (instead of whole days) was done using identical 
methods to the primary analysis. The Student’s t test 
was used to compare mean differences in length of stay. 
A worst­case scenario sensitivity analysis of the primary 
outcome was done by assigning the longest possible 
initial hospital day to those patients who were missing 
follow­up forms in the ambulatory care arm.
Continuous secondary outcome measures were 
analysed using ANCOVA adjusting for baseline scores. 
The adjusted mean difference between treatment arms 
was calculated with 95% confidence interval and p values. 
Categorical secondary outcome measures were analysed 
using the χ² test. Time­to­event secondary outcome 
measures were analysed in the same way as time­to­event 
analysis of the primary outcome measure.
Prespecified subgroup analyses of the primary outcome 
were done for gender, previous pneumothorax, and 
tobacco and marijuana smoking history (ever vs never), 
Patients receiving 
ambulatory care 
(n=117)
Patients receiving 
standard care 
(n=119)
Gender
Female 21 (18%) 22 (18%)
Male 96 (82%) 97 (82%)
Age (mean [SD]) 31 (8) 30 (9)
Ethnicity
Asian 2 (2%) 5 (4%)
Black, African, or Caribbean 1 (1%) 3 (3%)
Mixed or multiple ethnicity 1 (1%) 1 (1%)
Other 1 (1%) 2 (2%)
Unknown 1 (1%) 1 (1%)
White 111 (95%) 107 (90%)
Hours of pneumothorax before admission*
Median (IQR) 15 (4–72); n=105 23 (5–48); n=112
Mean (SD) 59 (132); n=105 58 (147); n=112
Size of pneumothorax
<4 cm 49 (42%) 49 (41%)
≥4 cm 68 (58%) 70 (59%)
Side of pneumothorax
Right 63 (54%) 68 (57%)
Left 54 (46%) 51 (43%)
Chest pain
Yes 104 (89%) 109 (92%)
No 13 (11%) 10 (8%)
Shortness of breath
Yes 104 (89%) 106 (89%)
No 13 (11%) 13 (11%)
Previous procedure to treat pneumothorax
No 96 (82%) 106 (89%)
Yes 21 (18%) 13 (11%)
Previous pneumothorax
No 90 (77%) 87 (73%)
Yes 26 (22%) 32 (27%)
Missing data 1 (1%) ··
(Table 1 continues in next column)
Patients receiving 
ambulatory care 
(n=117)
Patients receiving 
standard care 
(n=119)
(Continued from previous column)
Previous other lung disease
No 109 (93%) 113 (95%)
Yes 5 (4%) 6 (5%)
Unknown 1 (1%) ··
Missing data 2 (2%) ··
Cardiovascular disease
No 113 (97%) 100 (100%)
Yes 3 (3%) ··
Missing 1 (1%) ··
Renal disease
No 115 (98%) 117 (98%)
Yes 1 (1%) 2 (2%)
Missing 1 (1%) ··
Family history of pneumothorax
No 100 (85%) 100 (84%)
Yes 7 (6%) 13 (11%)
Unknown 8 (7%) 6 (5%)
Missing 2 (2%) ··
Tobacco smoking status
Current smoker 61 (52%) 56 (47%)
Ex-smoker 18 (15%) 26 (22%)
Never smoked 35 (30%) 37 (31%)
Missing 2 (2%) ··
Unknown 1 (1%) ··
Marijuana smoking status
Never smoked 57 (49%) 55 (46%)
Current smoker 35 (30%) 31 (26%)
Ex-smoker 20 (17%) 28 (24%)
Unknown 3 (3%) 5 (4%)
Missing 2 (2%) ··
Tobacco smoking pack-years 
for current and previous 
smokers (median [IQR])
8 (5–12); n=74 7 (5–11); n=78
Data are n (%) unless otherwise indicated. *Not all patients had available data.
Table 1: Baseline characteristics by treatment allocation
Articles
44 www.thelancet.com   Vol 396   July 4, 2020
using tests of interaction in Cox regression models 
for the primary outcome. All results are reported in 
concordance with CONSORT standards.17 All analyses 
were done using Stata (version 15, StataCorp 2017, USA).
The trial was prospectively registered with the 
International Standard Randomised Clinical Trials 
Number ISRCTN79151659.
Role of the funding source
Neither of the funding sources were involved in the study 
design, data collection, data analysis, data interpretation, 
or writing of the report. The corresponding author had 
full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
We recruited patients between August 27, 2015, and 
March 12, 2019. After approaching 776 potentially eligible 
patients, we reached our target of 236 (30%) participants, 
of whom 117 were assigned to ambulatory care and 119 to 
standard care (figure 1). The mean age at recruitment was 
30 years (SD 8). 193 (82%) patients were male, 58 (25%) 
had a history of previous pneumothorax, and 20 (8%) had 
a family history (first­degree or second­degree relative) of 
pneumothorax (table 1). 161 (68%) patients were current 
or former tobacco smokers, with a median pack­year 
history for both groups combined of 8 (IQR 5–12), and 
114 (48%) were current or former marijuana smokers 
(table 1). Most patients were symp tomatic with either 
chest pain (213 [90%]) or shortness of breath (210 [89%]).
For the primary outcome, we analysed 114 (97%) of 
117 patients who received ambulatory care and 113 (95%) 
of 119 who received standard care, because data was not 
available for the remaining patients. Among those who 
had ambulatory care, the median hospital stay in the first 
30 days was 0 days [IQR 0–3], which was significantly 
lower than in those who received standard care (4 days 
[IQR 0–8]; median difference 2 days, 95% CI 1–3; 
p<0·0001). The cumulative incidence of hospital stay 
(comprising any initial hospital stay plus re­admission 
days in hospital) is shown in figure 2. The difference 
in overall hospital stay during 30 days was also signif­
icant when calculated in hours (ambulatory median 
4·7 h [IQR 2·7–59·2] vs standard care median 74·7 h 
[IQR 6·3–178·2); p<0·0001; table 2). In the ambulatory 
care group, 73 (64%) of 114 patients with available data 
were discharged on the same day as admission, compared 
with 39 (34%) of 115 patients with available data in 
the standard care group (p<0·0001; appendix p 3). In 
24 patients (12 in ambulatory care; 12 in standard care), 
data were missing either at 1­week or at 30­days follow­
up, or both.
Re­admission rates were similar in the ambulatory and 
standard care groups (table 2). The time until successful 
completion of treatment, defined as when the ambulatory 
device was removed (ambulatory care) or when the patient 
had a successful outcome from aspiration or chest tube 
Patients receiving ambulatory 
care (n=117)
Patients receiving standard care 
(n=119)
Difference (95% CI)  p value
Patients with 
available data
Result Patients with 
available data
Result
Total hospital stay within 30 days after 
treatment (days)
114 0 (0 to 3) 113 4 (0 to 8) 2 (1 to 3) <0·0001
Total hospital stay within 30 days after 
treatment (h)
114 4·7 (2·7 to 59·2) 110 74·7 (6·3 to 178·2) 48·3 (19·4 to 71·8) <0·0001
Duration of initial hospital stay (days) 114 0 (0 to 1) 114 2 (0 to 6) 1 (0 to 2) <0·0001
Patients requiring further admission 
within 30 days (n [%])
117 17 (15%) 119 23 (19%) ·· ··
Duration of further admission (days) 17 4 (3 to 7) 23 4 (2 to 5) –1 (–3 to 1) 0·285
Time until successful completion of 
treatment (days)
111 3 (1 to 6) 115 2 (0 to 6) –1 (–2 to 0) 0·0040 
Patients discharged on same day as initial 
admission (n [%])
114 73 (64%) 115 39 (34%) ·· <0·0001
Data are median (IQR) unless otherwise indicated.
Table 2: Primary outcome according to treatment arm
Figure 2: Cumulative incidence curve showing time to discharge from 
randomisation plus re-admissions within 30 days
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removal after drainage (standard care), was significantly 
longer in patients in the ambulatory care group (table 2). 
The total time off work did not differ between groups, 
with a mean of 10·7 days (SD 11·9) in the ambulatory care 
group and 11·5 days (SD 13·0) in the standard care group.
The prespecified subgroups also showed differences 
in hospital stay, including for previous history of 
pneumothorax and smoking history (tobacco and mar­
ijuana; table 3). The tests for interactions were not 
significant in any of the subgroup analyses; hence, 
conclusions cannot be drawn about differential benefits 
in the subgroups.
In the worst­case scenario sensitivity analysis, median 
hospital stay in the first 30 days remained significantly 
shorter in those who received ambulatory care (1 day 
[IQR 0–6]) than in those who received standard care 
(4 days [IQR 0–8]; median difference 1 day, 95% CI 0–2; 
p=0·0057).
Because not all patients in the standard care arm had 
aspiration, we did a post­hoc analysis of the primary 
outcome excluding patients in whom no aspiration was 
done (ie, who proceeded directly to chest drain insertion 
as per clinician preference). Removing the 31 (26%) of 
119 patients in whom no aspiration was attempted in the 
standard care arm, the primary outcome still favoured 
the intervention arm. The median length of stay for 
patients in the standard care arm in whom aspiration 
was done was 3 days (IQR 0–8), and the median 
difference was 1 (95% CI 0–3; p=0·0001).
Regarding the secondary outcomes, initial treatment 
data was available for 227 (96%) of 236 patients. Docu­
mented per­protocol compliance with allocated treatment 
was 114 (97%) of 117 patients receiving ambulatory care 
and 113 (95%) of 119 patients receiving standard care. 
Among 119 patients receiving standard care, initial 
management was pleural aspiration in 81 (68%) patients, 
38 (47%) of whom subsequently required chest drain 
insertion. 31 (26%) of 119 patients receiving standard 
care were initially managed with a chest drain (table 4).
Following the initial intervention, patients who received 
ambulatory care required fewer total pleural procedures 
(mean 1·2 [SD 0·5]) than did those who received standard 
care (mean 1·4 [SD 0·7]; p=0·0327), and 40 (33·6%) of 
119 patients who received standard care required one or 
Patients receiving ambulatory care 
(n=117)
Patients receiving standard care 
(n=119)
Median difference 
(95% CI)
p value
Patients with 
available data
Result Patients with 
available data
Result
Gender ·· ·· ·· ·· ·· 0·518
Female 21 2 (0–6) 20 5 (2–11) 2 (0–5) ··
Male 93 0 (0–2) 94 3 (0–7) 2 (1–3) ··
Previous pneumothorax ·· ·· ·· ·· ·· 0·445
Yes 24 0 (0–5) 30 4 (0–8) 1 (0–5) ··
No 89 0 (0–3) 84 4 (1–8) 2 (1–3) ··
Tobacco smoking history ·· ·· ·· ·· ·· 0·209
Ever 76 0 (0–3) 79 4 (1–7) 2 (1–4) ··
Never 35 0 (0–2) 35 3 (0–11) 2 (0–5) ··
Marijuana smoking history ·· ·· ·· ·· ·· 0·254
Ever 53 0 (0–3) 56 4 (1–8) 3 (1–4) ··
Never 56 0 (0–3) 53 3 (0–7) 2 (0–4) ··
Data are median (IQR) unless otherwise indicated. p value compares difference between subgroups.
Table 3: Primary outcome by prespecified subgroup analysis
Patients receiving ambulatory 
care (n=117)
Patients receiving standard 
care (n=119)
p value
Patients with 
available data
Result Patients with 
available data
Result
Initial management
Pleural Vent inserted 117 114 (97%) 119 0 ··
Aspiration 117 0 119 81 (68%) ··
Chest tube 117 0 119 31 (26%) ··
Other 117 0 119 1 (1%) ··
Unknown* 117 3 (2%) 119 6 (5%) ··
Patients requiring 
additional procedure
114 24 (21%) 113 42 (35%) 0·0075
Additional procedure required
Further Pleural Vent 
replacement
114 2 (2%) 113 0 ··
Chest tube after 
aspiration
114 0 113 38 (32%) ··
Further chest tube 114 13 (11%) 113 4 (3%) ··
Larger chest tube 114 2 (2%) 113 1 (1%) ··
Repeat aspiration 114 4 (3%) 113 3 (3%) ··
Suction applied 11 1 (1%) 113 1 (1%)
Total number of 
procedures per patient 
(mean [SD])
114 1·2 (0·5) 113 1·4 (0·7) 0·033
Data are n (%) unless otherwise indicated. *Data not recorded on database.
Table 4: Secondary outcomes: need for further procedures
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more further pleural procedures (table 4). Surgical referral 
rates were similar in both groups, including 33 (28%) of 
117 patients who received ambulatory care and 26 (22%) of 
119 patients who had standard care. Of patients referred 
for surgery, 21 (64%) in ambulatory care and 19 (73%) in 
standard care then had a surgical procedure.
Mean pain and breathlessness VAS scores were high at 
baseline and improved with treatment in both treatment 
groups (figure 3). Reported pain after the first inter­
vention was similar in both groups and improved during 
days 1–4. There was no significant difference in analgesia 
use between the two groups during days 0–4 (appendix 
pp 5–6).
Among the study population, 1 week after completion of 
treatment, 26 (12%) of 220 patients had an ongoing 
pneumothorax (not requiring admission) and 27 (12%) had 
a recurrence (appendix p 7). The proportion of patients 
with recurrence at day 7 was lower in the ambulatory care 
group (8 [7%] of 110 patients) than in the standard care 
group (19 [19%] of 110 patients; p=0·02). Of 19 patients 
receiving standard care with recurrence, 10 (53%) were 
initially treated with aspiration, five (26%) had aspiration 
then chest tube insertion, and four (21%) had chest tube 
insertion. A further 19 patients (9%) had a recurrence 
between day 7 and day 30.
Follow­up data were available up to 12 months for 
181 (77%) of 236 patients, with the remainder lost to 
follow­up. Recurrence rates from 1–12 months were 
Patients 
receiving 
ambulatory 
care (n=117)
Patients 
receiving 
standard 
care (n=119)
p value
Any serious adverse event or 
adverse event
64 (55%) 46 (39%) 0·0135
Serious adverse events 14 (12%) 0 <0·0001
Serious adverse events related to treatment* 
Enlarging pneumothorax† 4 (3%) 0 ··
Device blocked or kinked† 2 (2%) 0 ··
Device dislodgement† 1 (1%) 0 ··
Re-expansion pulmonary 
oedema (asymptomatic)
1 (1%) 0 ··
Device leakage† 1 (1%) 0 ··
Admitted for suction 1 (1%) 0 ··
Serious adverse events unrelated to treatment*
Unrecognised 
haemopneumothorax†
3 (3%) 0 ··
Pleurisy 1 (1%) 0 ··
Adverse events related to 
treatment*
51 (44%) 40 (34%) 0·1154
Pain at tube site 36 (31%) 36 (30%) ··
 Haematoma or bleeding 8 (7%) 2 (2%) ··
 Subcutaneous emphysema 7 (6%) 7 (6%) ··
Site infection 1 (1%) 1 (1%) ··
Tube displacement 2 (2%) 1 (1%) ··
Drainage device failure 3 (3%) 1 (1%) ··
Blocked tube 1 (1%) 1 (1%) ··
Fluid within tube 3 (3%) 0 ··
Other chest pain 2 (2%) 4 (3%) ··
Erythema or itch 2 (2%) 0 ··
Attendance at emergency 
department
1 (1%) 0 ··
Adverse events not related to 
treatment
9 (8%) 10 (8%) 0·8410
Chest infection 0 3 (3%) ··
Infection at site 2 (2%) 1 (1%) ··
Other chest pain 1 (1%) 1 (1%) ··
Vasovagal episode 2 (2%) 0 ··
Shortness of breath 1 (1%) 1 (1%) ··
Blood in pleural effusion 1 (1%) 0 ··
Pleural effusion 0 1 (1%) ··
Erythema or itch 0 1 (1%) ··
Fainting 1 (1%) 0 ··
Nausea and vomiting 0 1 (1%) ··
Per rectum bleeding 1 (1%) 0 ··
Viral infection 0 1 (1%) ··
Attendance at emergency 
department
1 (1%) 0 ··
Data are n (%). *Patients could have more than one adverse event. †Required 
admission and chest tube insertion.
Table 5: Adverse events
Figure 3: Visual Analogue Score of pain (A) and breathlessness (B)
Scores shown for baseline (at enrolment), after the initial procedure, and then 
daily on days 1–4. Bars represent confidence intervals. 
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similar in the ambulatory and standard care arms 
(appendix p 7). The overall rate of ipsilateral pneumothorax 
recurrence up to 12 months was 24% for the ambulatory 
arm and 28% for the standard care arm (p=0·22; 
appendix p 8). Recurrence­free survival curves are shown 
in the appendix (p 4).
110 (47%) of 236 patients had adverse events (table 5), 
including 64 (55%) of 117 patients in the ambulatory care 
arm and 46 (39%) of 119 in the standard care arm. 
97 (39%) patients had intervention­related or treatment­
related adverse events.
All 14 serious adverse events occurred in patients who 
received ambulatory care, and these events were all rated 
as serious on the basis of the need for re­admission to 
hospital (table 5). Eight (57%) of the 14 serious adverse 
events were related to the intervention (and some patients 
had more than one serious adverse event): four (3%) of 
117 patients receiving ambulatory care had an enlarging 
pneumothorax on repeat chest radiography at outpa­
tient review, which required admission and chest tube 
insertion; for two (2%) patients the device malfunctioned 
(tube kinked or blocked); one (1%) patient had radio­
graphic evidence of (asymptomatic) pulmonary oedema at 
review on day 1, but was admitted for observation without 
overnight stay; one (1%) device was leaking fluid; the 
device dislodged in one (1%) patient, requiring chest tube 
placement; and one (1%) patient was admitted for suction. 
The remaining four serious adverse events were haemo­
pneumothorax (n=3 [3%]) and pleurisy (n=1 [1%]), which 
were all judged to be unrelated to the intervention. All 
three patients with unrecognised haemopneumothorax 
had chest radiographic evidence of significant fluid (in 
addition to pneumothorax) before the intervention. These 
three patients either had surgery or CT angiography that 
did not identify an intervention­associated source of 
bleeding.
The most frequent non­serious adverse events were 
pain at the insertion site, haematoma or bleeding, surgical 
or subcutaneous emphysema, and failure of the drainage 
device (table 5).
Discussion
This multicentre, open­label, randomised controlled 
tri al compared an ambulatory treatment strategy for 
primary spontaneous pneumothorax with standard care 
using evidence­based guidelines (aspiration, chest drain 
insertion, or both), using clinically relevant outcomes 
including the duration of hospital stay during the first 
30 days following intervention. The results show the 
efficacy of the ambulatory strategy, with most patients 
successfully managed as outpatients. This finding is 
supported by analysis of the primary outcome by initial 
hospital and overall stay in both whole days and number 
of hours.
Although 24 (21%) of 114 patients who had ambulatory 
care required at least one further procedure, patients in 
this group required significantly fewer procedures overall 
than those who received standard care. Patients in 
the ambulatory group had longer treatment duration 
(ie, time with ambulatory device in place) than did the 
standard care group (ie, time with chest drain in place). 
This difference is probably due to a number of factors. 
First, physicians might have been more cautious in 
managing patients with the ambulatory device and left 
the device in situ longer to ensure it was not removed too 
soon. Second, because patients in the ambulatory care 
group were being managed as outpatients and reviewed 
every 24 h, there were fewer opportunities to assess 
whether the pneumothorax had resolved than there were 
for those with a chest tube, who were treated in hospital 
and potentially reviewed many times per day.
Serious adverse events, defined as those needing 
admission to hospital, occurred exclusively in the 
ambulatory care arm. Serious adverse events related 
to treatment included enlargement of pneumothorax 
despite the ambulatory device being in place and device 
blockage and kinking, requiring chest tube insertion 
and hospitalisation. In the ambulatory care group, 
three patients had unrecognised haemopneumothoraces, 
which at review were not considered related to the inter­
vention. Although this higher rate of serious adverse 
events is clearly important, by the nature of its definition it 
is biased against the ambulatory arm. Insertion of a chest 
tube (eg, after failed aspiration) and admission to hospital 
was not a possible serious adverse event in the standard 
care arm because this constituted normal care. Therefore, 
any adverse event in a patient already hospitalised, 
regardless of the primary intervention, requires careful 
interpretation. Nonetheless, the increased adverse event 
rate in the ambulatory arm should be accounted for when 
using an ambulatory pneumothorax strategy.
No significant differences between intervention groups 
were observed in secondary outcome measures in terms 
of VAS pain or breathlessness scores, time off work, and 
overall recurrence at 30 days. However, the pneumothorax 
recurrence rate within 7 days of treatment completion was 
higher in those who received standard care. Recurrence at 
this early stage is unusual and is often presumed to be due 
to enlargement of an ongoing pneumothorax. As a result, 
investigators classified patients with pneumothorax 
within 7 days into two categories: ongoing if there had 
been incomplete re­expansion on chest radiograph at 
completion of treatment, or new recurrence if the 
pneumothorax had fully resolved on the last chest 
radiograph. The excess recurrence in patients receiving 
standard care was not entirely due to patients treated with 
aspiration alone, because they accounted for less than 
53% of those with early recurrence.
Longer­term recurrence rates (1–12 months) were 
similar between the two groups. Despite excess recurrence 
in the standard care arm by 30 days, the cumulative rate of 
first ipsilateral recurrence was not statistically different at 
12 months. The overall rate of recurrence (27%) is 
consistent with previous large epidemiological studies.1,12
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A 2020 randomised trial3 in primary spontaneous 
pneumothorax compared conservative management (ie, no 
intervention) with standard care (ie, chest tube insertion),3 
reporting that the conservative approach was non­inferior 
to standard care in the primary outcome of resolution of 
pneumothorax on chest radiograph at 8 weeks. We have 
concerns about the widespread adoption of this approach. 
First, the trial screened more than 2600 patients to ran­
domly assign 316, and it required 39 sites recruiting for 
6 years. Excluding patients with previous pneumothorax 
would automatically exclude about 25% of the population. 
The reasons for which all other patients were excluded in 
the trial are unclear. The trial might therefore be applicable 
only to those patients with minimal symptoms, and it is 
already recognised that conservative management is whol­
ly appropriate in some cases of primary spontaneous 
pneumothorax (as stated in the 2010 BTS guidelines4). 
Second, the primary outcome was radiological, rather than 
patient­centred (eg, symptoms, time in hospital). Few data 
are presented on patient symptoms except at 2 weeks and 
what was termed an overall satisfaction score. Therefore, 
although the conservative treatment study should be 
applauded for showing reduced inpatient hospital stay, we 
would suggest that symptomatic patients who choose or 
are chosen by the treating physicians for intervention 
should be considered for the ambulatory treatment strategy, 
which is shown here to be effective and reasonably safe.
There are limitations to this study. Some eligible patients 
were not enrolled because they presented out of the 
0900–1700 National Health Service working hours or when 
no trained members of staff were available. This factor 
introduces a potential recruitment bias, be cause patients 
presenting out of hours could be more unwell, and 
thus ambulatory management should be used cautiously 
in those patients. However, this prospective trial was 
pragmatic in its design and the patients who enrolled 
were likely to represent those suitable for ambulatory 
management. The study was necessarily open label with 
both patients and physicians aware of treatment allocation; 
however, the use of objective and identical discharge 
criteria were used for the primary outcome measure to 
ensure balance between treatment groups. Finally, not all 
patients in the standard care arm had pleural aspiration as 
initial management, which could have introduced bias to­
wards the ambulatory arm. However, a post­hoc analysis 
excluding these patients showed that the primary outcome 
remained significantly different between the two arms.
Considering the data in the present study, what is now 
the optimal treatment for patients with primary 
spontaneous pneumothorax who require treatment? To 
our knowledge, our results show for the first time 
evidence of effective use of an entirely ambulatory strategy 
in patients with symptomatic primary spontaneous 
pneumothorax, as compared with current evidence based 
standard care. The ambulatory strategy was associated 
with reduced hospital stay and did not result in higher 
surgical or recurrence rates, but it did show an increase in 
adverse events related to readmission. Despite these 
readmissions, the total number of pleural procedures 
required and median hospital stay were significantly lower 
in patients in the ambulatory arm. These results have 
important implications for practice and suggest that future 
guidelines should include an ambulatory treatment option. 
We argue that this study provides strong evidence that the 
ambulatory strategy should replace the initial treatment 
(both aspiration and chest tube insertion) that forms the 
basis of current management guidelines. The ambulatory 
device used in this trial was the Pleural Vent (Rocket 
Medical). Ambulatory treatment might be just as effective 
with any ambulatory treatment strategy (eg, a chest drain 
attached to a one­way valve), but other devices were not 
tested in this study. It should be noted, however, that an 
ambulatory treatment strategy for primary spontaneous 
pneumothorax will require health­care services to develop 
ambulatory care facilities to allow patients to be safely 
followed up with the device in situ.
In conclusion, in patients with primary spontaneous 
pneumothorax, ambulatory management significantly 
reduces the duration of hospital stay during 30 days. 
Outpatient management is now a reasonable and prob ably 
preferable option in the management of this condition.
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